KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) CEO Benjamin L. Palleiko sold 14,400 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at $2,468,697.48. This trade represents a 5.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
KalVista Pharmaceuticals Stock Up 3.5 %
Shares of KalVista Pharmaceuticals stock opened at $9.28 on Friday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.39 and a 12-month high of $16.88. The firm has a market capitalization of $400.82 million, a PE ratio of -2.63 and a beta of 0.92. The stock’s fifty day moving average is $11.04 and its 200-day moving average is $11.99.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. Analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.
Institutional Trading of KalVista Pharmaceuticals
Wall Street Analyst Weigh In
A number of research firms recently commented on KALV. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.
View Our Latest Report on KALV
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Articles
- Five stocks we like better than KalVista Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- Symbotic Is Up Nearly 50% in 3 Months: Why It Can Keep Winning
- What is a Death Cross in Stocks?
- QuantumScape: High-Risk, High-Reward Solid-State Battery Play?
- Trading Halts Explained
- Santa Claus Rally: 4 Reasons Stocks Could End the Year Strong
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.